Advisory From the American Heart Association The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science

[1]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[2]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[3]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[4]  E. Puré,et al.  Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism , 2005, Circulation.

[5]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[6]  G. FitzGerald.  Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.

[7]  D. Fitzgerald,et al.  Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis , 2003, Circulation.

[8]  B. Bennett,et al.  Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. , 2003, Cardiovascular research.

[9]  K. Chu,et al.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. , 2002, The New England journal of medicine.

[10]  J. Morrow,et al.  Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice , 2002, Circulation.

[11]  E. Falk,et al.  No Effect of Cyclooxygenase Inhibition on Plaque Size in Atherosclerosis-prone Mice , 2002, Scandinavian cardiovascular journal : SCJ.

[12]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[13]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[14]  G. FitzGerald,et al.  Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[16]  J. Vane,et al.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. , 1976, Prostaglandins.